Jens Præstgaard

3.5k total citations · 2 hit papers
41 papers, 2.4k citations indexed

About

Jens Præstgaard is a scholar working on Molecular Biology, Epidemiology and Physiology. According to data from OpenAlex, Jens Præstgaard has authored 41 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Epidemiology and 9 papers in Physiology. Recurrent topics in Jens Præstgaard's work include Hepatitis C virus research (6 papers), Muscle Physiology and Disorders (4 papers) and Microscopic Colitis (4 papers). Jens Præstgaard is often cited by papers focused on Hepatitis C virus research (6 papers), Muscle Physiology and Disorders (4 papers) and Microscopic Colitis (4 papers). Jens Præstgaard collaborates with scholars based in United States, Switzerland and Germany. Jens Præstgaard's co-authors include Jon A. Wellner, Ronenn Roubenoff, Didier Laurent, Daniel Rooks, David J. Glass, Nicholas M. Valiante, Baisong Huang, Holden T. Maecker, Giuseppe Del Giudice and Michael A. Lonetto and has published in prestigious journals such as Annals of Internal Medicine, Hepatology and Neurology.

In The Last Decade

Jens Præstgaard

39 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

mTOR inhibition improves immune function in the elderly

2014 563 citations Joan B. Mannick, Giuseppe Del Giudice et al. Science Translational Medicine profile →
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity

2021 183 citations Daniel Rooks, Didier Laurent et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jens Præstgaard United States	21	891	608	382	229	217	41	2.4k
Niall Anderson United Kingdom	34	552 0.6×	321 0.5×	807 2.1×	482 2.1×	188 0.9×	84	3.5k
Weiliang Qiu United States	40	1.5k 1.7×	789 1.3×	296 0.8×	324 1.4×	43 0.2×	115	4.2k
Ulrich Broeckel United States	37	1.1k 1.3×	141 0.2×	358 0.9×	402 1.8×	179 0.8×	95	3.9k
Lang Li United States	39	2.0k 2.3×	172 0.3×	326 0.9×	232 1.0×	226 1.0×	158	5.1k
Qing H. Meng United States	36	1.5k 1.7×	576 0.9×	295 0.8×	334 1.5×	74 0.3×	148	4.2k
Guo Wei United States	18	4.1k 4.6×	479 0.8×	283 0.7×	481 2.1×	281 1.3×	40	6.2k
Douglas L. Schmucker United States	32	701 0.8×	430 0.7×	679 1.8×	341 1.5×	155 0.7×	64	3.0k
Ping Xu China	24	977 1.1×	345 0.6×	448 1.2×	222 1.0×	44 0.2×	64	2.5k
Sudeep Pushpakom United Kingdom	13	1.6k 1.8×	183 0.3×	459 1.2×	216 0.9×	287 1.3×	25	3.7k
Jing Gong China	31	1.0k 1.2×	200 0.3×	302 0.8×	271 1.2×	374 1.7×	101	2.9k

Countries citing papers authored by Jens Præstgaard

Since Specialization

Citations

This map shows the geographic impact of Jens Præstgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Præstgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Præstgaard more than expected).

Fields of papers citing papers by Jens Præstgaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Præstgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Præstgaard. The network helps show where Jens Præstgaard may publish in the future.

Co-authorship network of co-authors of Jens Præstgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Præstgaard. A scholar is included among the top collaborators of Jens Præstgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Præstgaard. Jens Præstgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pétricoul, Olivier, U. Schramm, Olivier David, et al.. (2022). Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338). Clinical Pharmacokinetics. 62(1). 141–155. 10 indexed citations

Argent, Rob, Alan Bourke, Amir Muaremi, et al.. (2022). VALIDITY AND RELIABILITY OF A BODY-WORN BIOMECHANICAL SENSOR PLATFORM FOR GAIT ANALYSIS. Osteoarthritis and Cartilage. 30. S148–S149.

Mueller, Arne, Elaine Paterson, Jens Præstgaard, et al.. (2021). Digital endpoints for self‐administered home‐based functional assessment in pediatric Friedreich’s ataxia. Annals of Clinical and Translational Neurology. 8(9). 1845–1856. 15 indexed citations

Millar, Neal L., Iain B. McInnes, Linda Mindeholm, et al.. (2021). POS0020 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ROTATOR CUFF TENDINOPATHY: A 24-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II PROOF-OF-CONCEPT TRIAL. Annals of the Rheumatic Diseases. 80. 211–212. 1 indexed citations

Mueller, Arne, Hölger Hoefling, Amir Muaremi, et al.. (2019). Continuous Digital Monitoring of Walking Speed in Frail Elderly Patients: Noninterventional Validation Study and Longitudinal Clinical Trial. JMIR mhealth and uhealth. 7(11). e15191–e15191. 39 indexed citations

Polkey, Michael I., Jens Præstgaard, Frits M.E. Franssen, et al.. (2018). Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine. 199(3). 313–320. 78 indexed citations

Hannesdóttir, Kristín, Oleksandr Sverdlov, Jelena Curcic, et al.. (2018). P4‐339: THE MEDIA STUDY: A NOVEL METHOD FOR EVALUATING DIGITAL ENDPOINTS IN ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 14(7S_Part_30).

Bhansali, Suraj G., Kathleen M. Mullane, Lillian Ting, et al.. (2014). Pharmacokinetics of LFF571 and Vancomycin in Patients with Moderate Clostridium difficile Infections. Antimicrobial Agents and Chemotherapy. 59(3). 1441–1445. 30 indexed citations

Mannick, Joan B., Giuseppe Del Giudice, Maria Lattanzi, et al.. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 6(268). 268ra179–268ra179. 563 indexed citations breakdown →

10.

Barve, Avantika, Steven J. Kovacs, Annick Ménétrey, et al.. (2014). The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Clinical Pharmacology in Drug Development. 4(1). 25–32. 5 indexed citations

11.

Abt, Peter L., Jens Præstgaard, Sharon West, & Richard Hasz. (2013). Donor Hemodynamic Profile Presages Graft Survival in Donation After Cardiac Death Liver Transplantation. Liver Transplantation. 20(2). 165–172. 24 indexed citations

12.

Leeds, Jennifer A., et al.. (2012). Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy. 56(8). 4459–4462. 53 indexed citations

13.

Præstgaard, Jens. (2011). A note on the power superiority of the restricted likelihood ratio test. Journal of Multivariate Analysis. 104(1). 1–15. 2 indexed citations

14.

Lawitz, Eric, Eliot Godofsky, Roman Rouzier, et al.. (2011). Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Research. 89(3). 238–245. 58 indexed citations

15.

Lawitz, Eric, R. Gary Rozier, Thomas Marbury, et al.. (2009). 622 SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS. Journal of Hepatology. 50. S229–S229. 5 indexed citations

16.

Balan, Vijayan, Daniel Nelson, Mark Sulkowski, et al.. (2003). 984 Molecular profiles of drug response in HCV infected patients during the first 4 weeks of therapy for chronic hepatitis C virus with pegylated interferon containing regimens or albuferon™. Hepatology. 38. 630–630. 4 indexed citations

17.

Waring, Jeffrey F., Robert A. Jolly, Rita Ciurlionis, et al.. (2001). Clustering of Hepatotoxins Based on Mechanism of Toxicity Using Gene Expression Profiles. Toxicology and Applied Pharmacology. 175(1). 28–42. 268 indexed citations

18.

Ross, James W., et al.. (1998). The accuracy of laboratory measurements in clinical chemistry: a study of 11 routine chemistry analytes in the College of American Pathologists Chemistry Survey with fresh frozen serum, definitive methods, and reference methods.. PubMed. 122(7). 587–608. 72 indexed citations

19.

Præstgaard, Jens & Jon A. Wellner. (1993). Exchangeably Weighted Bootstraps of the General Empirical Process. The Annals of Probability. 21(4). 152 indexed citations

20.

Præstgaard, Jens. (1991). Nonparametric estimation of actuarial values. Scandinavian Actuarial Journal. 1991(2). 129–143. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact